Thrombophilia, Thrombosis and Thromboprophylaxis in Pregnancy: For What and in Whom?


Journal

Hamostaseologie
ISSN: 2567-5761
Titre abrégé: Hamostaseologie
Pays: Germany
ID NLM: 8204531

Informations de publication

Date de publication:
Feb 2022
Historique:
entrez: 23 2 2022
pubmed: 24 2 2022
medline: 26 2 2022
Statut: ppublish

Résumé

Compared with nonpregnant women, pregnancy carries a four- to fivefold higher risk of venous thromboembolism (VTE). Despite increasing use of heparin prophylaxis in identified high-risk patients, pulmonary embolism still is the leading cause of maternal mortality in the western world. However, evidence on optimal use of thromboprophylaxis is scarce. Thrombophilia, the hereditary or acquired tendency to develop VTE, is also thought to be associated with complications in pregnancy, such as recurrent miscarriage and preeclampsia. In this review, the current evidence on optimal thromboprophylaxis in pregnancy is discussed, focusing primarily on VTE prevention strategies but also discussing the potential to prevent recurrent pregnancy complications with heparin in pregnant women with thrombophilia.

Identifiants

pubmed: 35196731
doi: 10.1055/a-1717-7663
doi:

Substances chimiques

Anticoagulants 0
Heparin, Low-Molecular-Weight 0
Heparin 9005-49-6

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

54-64

Informations de copyright

Thieme. All rights reserved.

Déclaration de conflit d'intérêts

The authors declare that they have no conflict of interest.

Auteurs

Saskia Middeldorp (S)

Department of Internal Medicine, Radboud Institute of Health Sciences (RIHS), Radboud University Medical Center, Nijmegen, The Netherlands.

Christiane Naue (C)

Division of Hematology, Department of Medicine I, University Hospital "Carl Gustav Carus" Dresden, Dresden, Germany.

Christina Köhler (C)

Division of Hematology, Department of Medicine I, University Hospital "Carl Gustav Carus" Dresden, Dresden, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH